The U.S. Food and Drug Administration (FDA) issued its final guidance on mandatory cosmetic product recalls on October 22, 2026, providing further clarification on the Agency’s authority to order the recall of cosmetic products under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
The guidance, titled “Questions and Answers Regarding Mandatory Cosmetics Recalls: Guidance for Industry,” addresses the implementation of Section 611 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which was added by MoCRA.
It explains the circumstances in which FDA may exercise its mandatory recall authority, the regulatory procedures involved and the responsibilities of cosmetic companies receiving recall-related orders.
Following the review of public comments on the draft guidance published on December 18, 2025, FDA finalized the document without substantive changes.
The final guidance represents an important development for cosmetic manufacturers, importers, distributors, brand owners and Responsible Persons supplying products to the U.S. market.
What Is FDA’s Mandatory Cosmetics Recall Authority Under MoCRA?
The Modernization of Cosmetics Regulation Act of 2022 introduced significant changes to the regulatory framework governing cosmetics in the United States.
Among these changes, MoCRA added Section 611 to the FD&C Act, granting FDA authority to require mandatory recalls of cosmetic products under specific circumstances.
Historically, most cosmetic recalls have been initiated voluntarily by manufacturers or distributors, often in coordination with FDA.
Under the expanded regulatory framework, FDA can intervene when certain legally defined conditions are met and a company fails to voluntarily cease distribution and recall the affected cosmetic product.
However, the existence of a regulatory violation alone does not automatically trigger FDA’s mandatory cosmetics recall authority.
When Can FDA Order a Mandatory Cosmetic Recall?
Under Section 611 of the FD&C Act, FDA must determine that two key conditions are met before exercising its mandatory recall authority.
1. The Cosmetic Product Is Adulterated or Misbranded
FDA must determine that there is a reasonable probability that the cosmetic product is adulterated under Section 601 or misbranded under Section 602 of the FD&C Act.
Potential concerns may relate to unsafe ingredients, contamination, manufacturing conditions, insufficient safety substantiation or misleading labelling.
2. The Product Presents a Serious Health Risk
FDA must also determine that there is a reasonable probability that the use of or exposure to the cosmetic product will cause serious adverse health consequences or death (SAHCOD).
This additional requirement is important because not every instance of non-compliance meets the threshold for a mandatory recall under Section 611.
FDA evaluates the nature of the violation together with the potential severity of the associated health risk.
How Does FDA’s Mandatory Cosmetics Recall Process Work?
The final guidance explains the regulatory process FDA follows when considering a mandatory cosmetic recall.
Step 1: Opportunity for Voluntary Recall
When FDA determines that the statutory criteria are met, it first provides the Responsible Person with an opportunity to voluntarily cease distribution and recall the affected cosmetic product.
FDA communicates this opportunity in writing.
The Agency continues to encourage voluntary recalls of violative cosmetics and expects that most cosmetic recalls will continue to be conducted voluntarily.
Step 2: Order to Cease Distribution
If the Responsible Person refuses or fails to voluntarily cease distribution and recall the cosmetic within the conditions specified by FDA, the Agency may issue an order requiring the immediate cessation of distribution.
The Responsible Person must comply with the order.
Step 3: Opportunity for an Informal Hearing
Following the distribution cessation order, FDA must provide the Responsible Person with an opportunity for an informal hearing.
If the hearing is granted, it must take place no later than 10 days after the issuance of the order.
The hearing addresses whether sufficient evidence exists to justify FDA’s action.
Step 4: Final Regulatory Decision
After providing the opportunity for an informal hearing, FDA may:
- Vacate the order if insufficient grounds exist.
- Continue the distribution cessation order until a specified date.
- Amend the order to require a mandatory recall.
A mandatory recall order may specify notification requirements, recall timelines and schedules for providing updates to FDA.
Voluntary vs. Mandatory Cosmetic Recalls: What Is the Difference?
Although MoCRA expanded FDA’s recall authority, voluntary recalls remain an important mechanism for addressing non-compliant cosmetic products.
| Criteria | Voluntary Recall | Mandatory Recall |
| Initiation | Company-led, independently or following FDA involvement | FDA exercising statutory authority |
| Regulatory framework | Generally conducted under 21 CFR Part 7 | FD&C Act Section 611 |
| Health risk | May involve different levels of risk | Requires reasonable probability of serious adverse health consequences or death |
| Implementation | Company conducts the recall voluntarily | Company must comply with FDA’s binding order |
| Regulatory involvement | FDA may monitor and evaluate the recall | FDA directs the mandatory recall process |
The distinction is particularly relevant to cosmetic businesses developing internal product safety, compliance and recall procedures.
Which Cosmetic Products Are Subject to FDA’s Mandatory Recall Authority?
FDA’s mandatory cosmetics recall authority applies to products meeting the definition of a cosmetic under Section 201(i) of the FD&C Act.
However, products that are also subject to the drug or medical device requirements of Chapter V of the FD&C Act are not covered by the mandatory cosmetic recall provisions of Section 611.
Such products may be subject to other applicable mandatory recall authorities.
The regulatory classification of a product is therefore an important consideration when determining the applicable recall requirements.
What Evidence May FDA Consider Before Ordering a Recall?
The final guidance explains that FDA may consider various sources of information when evaluating whether a cosmetic product presents a serious health risk.
These may include:
- Significant safety findings identified during facility inspections.
- Laboratory analysis of raw materials, finished cosmetic products or manufacturing environments.
- Epidemiological information associated with product-related illnesses or injuries.
- Available serious adverse event reports.
- Consumer complaints and industry reports.
- The vulnerability of the intended or exposed consumer population.
- Whether the Responsible Person has failed to voluntarily cease distribution or initiate a recall.
FDA evaluates the available evidence when determining whether the statutory criteria for a mandatory cosmetic recall have been met.
Responsibilities of the Responsible Person Under MoCRA
Under MoCRA, the Responsible Person is generally the manufacturer, packer or distributor whose name appears on the cosmetic product label in accordance with the applicable statutory requirements.
When FDA issues an order under Section 611, the Responsible Person must comply with the applicable requirements.
Depending on the circumstances, FDA may also require notifications to manufacturers, distributors, importers, retailers or the public.
A mandatory recall order may establish specific communication requirements, recall timelines and reporting obligations.
Failure or refusal to comply with a binding order may result in enforcement action, including potential injunctions or criminal prosecution under applicable provisions of the FD&C Act.
How Should Cosmetic Companies Prepare for FDA Recall Requirements?
The final guidance highlights the importance of effective product safety management and recall readiness for businesses operating in the U.S. cosmetics market.
Companies should consider reviewing the following areas:
1. Cosmetic Recall Procedures
Evaluate internal processes for identifying potentially unsafe or non-compliant cosmetic products and initiating appropriate corrective actions.
2. Product Traceability
Maintain appropriate information concerning manufacturing batches, suppliers, distributors and product distribution channels to support efficient recall activities.
3. Safety Substantiation Documentation
Review the adequacy of documentation supporting cosmetic product safety under applicable MoCRA requirements.
4. Adverse Event and Complaint Management
Assess procedures for receiving, investigating and documenting consumer complaints and serious adverse events.
5. Regulatory Communication
Establish clear responsibilities for handling FDA communications, regulatory requests and potential recall-related orders.
These measures can support effective risk management and help companies respond appropriately to potential product safety issues.
Does the Final FDA Guidance Create New Legally Binding Requirements?
FDA guidance documents generally communicate the Agency’s current thinking on regulatory matters.
The final mandatory cosmetics recalls guidance does not independently create new legally enforceable obligations.
Instead, it explains FDA’s interpretation and intended implementation of the mandatory recall authority already established under Section 611 of the FD&C Act.
Companies must therefore distinguish between the recommendations contained in the guidance and the binding statutory or regulatory requirements referenced in it.
What Does the Final FDA Guidance Mean for the Cosmetics Industry?
FDA’s final guidance on mandatory cosmetic recalls, issued on October 22, 2026, provides greater clarity regarding the Agency’s enforcement authority under MoCRA.
The guidance explains when FDA may require a mandatory recall, the opportunity provided for voluntary action, the procedural rights of Responsible Persons and the regulatory expectations associated with recall orders.
While FDA continues to encourage voluntary recalls, the authority established under Section 611 provides an additional mechanism for addressing cosmetic products that present a serious risk to public health.
For companies manufacturing, importing or distributing cosmetic products in the United States, product safety substantiation, traceability, adverse event management and recall preparedness remain important components of regulatory compliance.